谁在削木头
发表于 2025-3-23 11:20:11
978-3-030-56823-8Springer Nature Switzerland AG 2021
OVERT
发表于 2025-3-23 16:19:50
http://reply.papertrans.cn/84/8301/830082/830082_12.png
否认
发表于 2025-3-23 18:06:55
http://reply.papertrans.cn/84/8301/830082/830082_13.png
ALIAS
发表于 2025-3-24 02:10:47
Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principlesumor immune response. Glucocorticoids are the first-line agent, but they should be used with caution and limited in both dose and duration if possible. Early referral to rheumatology is the key to addressing the issues in these complex patients. More human trials using DMARDs and biologic treatments are necessary.
小官
发表于 2025-3-24 02:46:20
http://image.papertrans.cn/r/image/830082.jpg
抚慰
发表于 2025-3-24 09:25:35
https://doi.org/10.1007/978-3-030-56824-5Cancer immunotherapy and rheumatic diseases; Cancer immunotherapy and arthritis; Cancer immunotherapy
新星
发表于 2025-3-24 11:43:04
Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Polymyalgia Rheumatica clinical variant with potentially different pathogenesis, clinical course, and treatment responsiveness. While these patients can present classically, it seems they may also present with atypical clinical features and require higher than expected doses of glucocorticoids or even glucocorticoid-sparing agents.
JAMB
发表于 2025-3-24 18:02:43
http://reply.papertrans.cn/84/8301/830082/830082_18.png
FUSE
发表于 2025-3-24 19:16:50
Cancer Immunotherapy in Patients with Preexisting Inflammatory Arthritisexisting rheumatoid arthritis exposed to ICI for melanoma and followed longitudinally is presented in detail to highlight the clinical course and management challenges faced when caring for these patients.
V切开
发表于 2025-3-25 00:25:28
http://reply.papertrans.cn/84/8301/830082/830082_20.png